ALNY

Alnylam Pharmaceuticals, Inc.

156.92 USD
+3.06 (+1.99%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Alnylam Pharmaceuticals, Inc. stock is up 4.88% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 61.9% of the previous 20 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
18 Jun 18:12 19 Jul, 2024 175.00 PUT 118 7
20 Jun 15:06 21 Jun, 2024 170.00 PUT 19 80
20 Jun 15:14 19 Jul, 2024 150.00 PUT 21 2031
20 Jun 18:33 19 Jul, 2024 125.00 PUT 30 227
20 Jun 19:47 19 Jul, 2024 125.00 PUT 100 227
20 Jun 19:48 19 Jul, 2024 125.00 PUT 118 227
20 Jun 19:50 19 Jul, 2024 160.00 CALL 19 551
20 Jun 19:50 19 Jul, 2024 160.00 CALL 13 551
20 Jun 19:51 19 Jul, 2024 125.00 PUT 101 227
20 Jun 19:53 19 Jul, 2024 125.00 PUT 50 227

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.